@proterris.com
Proterris, a P2 clinical-stage firm, has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
About
Description
Proterris is a leading brand in the field of organ preservation, repair, and regeneration. Co-founded by Apeiron Partners, Columbia University, and Beth Israel Deaconess Medical Center, Proterris possesses a globally dominant intellectual property position in the therapeutic use of carbon monoxide (CO) for addressing crucial issues related to long transplant waiting lists and poor patient outcomes. Their ultimate goal is to build a global leader in organ preservation, repair, and regeneration.
Proterris offers a range of products and services aimed at advancing organ transplantation and improving patient outcomes. Their programs and pipeline consist of innovative solutions such as PRO-301, PRO-303, and PRO-304, which are dedicated to revolutionizing the field of organ repair and regeneration. The brand boasts a team of highly qualified professionals, including Jeff Wager as the Executive Chair, Stefan Ryter as the Senior Scientist and Acting President, Harry Lander as the SVP of Cell Therapies, Kouroush Saeb-Parsy as the Chief Medical Officer, and Ben Perrone as the Director of BD & Finance.
Together, they bring a wealth of expertise and experience to the Proterris team. With their cutting-edge science, Proterris is poised to make significant contributions to the medical community, transforming the landscape of organ transplantation and improving the lives of patients worldwide
Company Type
Privately Held
Company Size
2-10
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories